Rohini Janivara

Ms. Rohini Janivara

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AWAnqi Wang
Anqi Wang
JSJiayi Shen
Jiayi Shen
ARAlex A. Rodriguez
Alex A. Rodriguez
ESEdward J. Saunders
Edward J. Saunders
FCFei Chen
Fei Chen
CHChristopher A. Haiman
Christopher A. Haiman

2 October 2024 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RJRohini Janivara
Rohini Janivara
WCWenlong C. Chen
Wenlong C. Chen
UHUjani Hazra
Ujani Hazra
SBShakuntala Baichoo
Shakuntala Baichoo
IAIlir Agalliu
Ilir Agalliu
TRTimothy R. Rebbeck
Timothy R. Rebbeck

10 February 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
THThomas J. Hoffmann
Thomas J. Hoffmann
RGRebecca Graff
Rebecca Graff
RMRavi K. Madduri
Ravi K. Madduri
ARAlex A. Rodriguez
Alex A. Rodriguez
CCClinton L. Cario
Clinton L. Cario
JWJohn S. Witte
John S. Witte
We conducted a multiancestry genome-wide association study of prostate-specific antigen (PSA) levels in 296,754 men (211,342 European ancestry, 58,236 African ancestry, 23,546 Hispanic/Latino and 3,630 Asian ancestry; 96.5% of participants were from the Million Veteran Program). We identified 318 independent genome-wide significant (P ≤ 5 × 10−8) variants, 184 of which were novel. Most demonstrated evidence of replication in an independent cohort (n = 95,768). Meta-analyzing discovery and replication (n = 392,522) identified 447 variants, of which a further 111 were novel. Out-of-sample variance in PSA explained by our genome-wide polygenic risk scores ranged from 11.6% to 16.6% for European ancestry, 5.5% to 9.5% for African ancestry, 13.5% to 18.2% for Hispanic/Latino and 8.6% to 15.3% for Asian ancestry and decreased with increasing age. Midlife genetically adjusted PSA levels were more strongly associated with overall and aggressive prostate cancer than unadjusted PSA levels. Our study highlights how including proportionally more participants from underrepresented populations improves genetic prediction of PSA levels, offering potential to personalize prostate cancer screening.

25 December 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
SMSusmita Mandal
Susmita Mandal
TTTanishq Tejaswi
Tanishq Tejaswi
RJRohini Janivara
Rohini Janivara
SSSyamanthak Srikrishnan
Syamanthak Srikrishnan
PTPradipti Thakur
Pradipti Thakur
MJMohit Kumar Jolly
Mohit Kumar Jolly
Epithelial-mesenchymal plasticity (EMP) underlies embryonic development, wound healing, and cancer metastasis and fibrosis. Cancer cells exhibiting EMP often have more aggressive behavior, characterized by drug resistance, and tumor-initiating and immuno-evasive traits. Thus, the EMP status of cancer cells can be a critical indicator of patient prognosis. Here, we compare three distinct transcriptomic-based metrics—each derived using a different gene list and algorithm—that quantify the EMP spectrum. Our results for over 80 cancer-related RNA-seq datasets reveal a high degree of concordance among these metrics in quantifying the extent of EMP. Moreover, each metric, despite being trained on cancer expression profiles, recapitulates the expected changes in EMP scores for non-cancer contexts such as lung fibrosis and cellular reprogramming into induced pluripotent stem cells. Thus, we offer a scoring platform to quantify the extent of EMP in vitro and in vivo for diverse biological applications including cancer.

1 March 2026 in JCO Global Oncology
Verified
Journal Article
Closed access
IOIyanuoluwa Odole
Iyanuoluwa Odole
CACaroline Andrews
Caroline Andrews
IAIlir Agalliu
Ilir Agalliu
TRThomas Rohan
Thomas Rohan
PFPedro W. Fernandez
Pedro W. Fernandez
TRTimothy R. Rebbeck
Timothy R. Rebbeck
PURPOSE: African ancestry and family history (FHx) of prostate cancer (CaP) are among the few established CaP risk factors. Few studies have evaluated the association of FHx of CaP with the risk of this disease in African men. METHODS: Using the Men of African Descent and Carcinoma of the Prostate (MADCaP) network, we evaluated the association of self-reported FHx of CaP in fathers and brothers in a case-control study of 2,505 prostate cancer cases and 2,222 age-matched controls ascertained from seven centers across Africa. We compared the association of FHx and a 451-SNP polygenic risk score (PRS). RESULTS: Compared with controls, CaP cases had a higher proportion of fathers and/or brothers with a history of CaP overall, as well as in men age <60 or ≥60 years, and in those with/without aggressive CaP ( P < .001). A CaP diagnosis in fathers was associated with an odds ratio (OR) of 3.90 (95% CI, 2.66 to 5.72), 3.13 (95% CI, 2.02 to 4.86) in brothers, and 3.41 (95% CI, 2.51 to 4.64) in fathers and/or brothers. A one-unit PRS change was associated with an OR of 1.92 (95% CI, 1.72 to 2.13). Estimates for the PRS effect did not change substantially when FHx was included in the model. CONCLUSION: FHx is a strong predictor of CaP in African men. PRS is also associated with CaP largely independently of FHx. FHx may not always be reliably reported in Africa but the magnitude of recall or reporting bias is unlikely to have negated the observed association.

12 October 2023 in Research Square
Verified
Preprint
Open access
PDF file
TRTimothy Rebbeck
Timothy Rebbeck
RJRohini Janivara
Rohini Janivara
WCWenlong Chen
Wenlong Chen
UHUjani Hazra
Ujani Hazra
SBShakuntala Baichoo
Shakuntala Baichoo
JLJoseph Lachance
Joseph Lachance
Men of African descent have the highest prostate cancer (CaP) incidence and mortality rates, yet the genetic basis of CaP in African men has been understudied. We used genomic data from 3,963 CaP cases and 3,509 controls recruited in Ghana, Nigeria, Senegal, South Africa, and Uganda, to infer ancestry-specific genetic architectures and fine-mapped disease associations. Fifteen independent associations at 8q24.21, 6q22.1, and 11q13.3 reached genome-wide significance, including four novel associations. Intriguingly, multiple lead SNPs are private alleles, a pattern arising from recent mutations and the out-of-Africa bottleneck. These African-specific alleles contribute to haplotypes with odds ratios above 2.4. We found that the genetic architecture of CaP differs across Africa, with effect size differences contributing more to this heterogeneity than allele frequency differences. Population genetic analyses reveal that African CaP associations are largely governed by neutral evolution. Collectively, our findings emphasize the utility of conducting genetic studies that use diverse populations.